Homepage > Company > Media > Pharma News > 2019 > Jazz Pharma's sleep disorder drug gets European panel backing

Jazz Pharma's sleep disorder drug gets European panel backing

(Reuters) - Jazz Pharmaceuticals Plc’s treatment for a form of sleep disorder has been recommended for approval in Europe by a panel of the European Medicines Agency (EMA), the regulator said on Friday.

Solriamfetol, which will be branded as Sunosi, has been backed for the treatment of excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea (OSA), the EMA's human medicines committee (CHMP) said here.

The drug was approved in the United States earlier this year and is part of the company’s attempts to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, which faced a setback last year.

OSA is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start, while narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden bouts of sleep.

While final approvals are done by the European Commission, it generally follows the panel’s recommendation and announces its decision within a couple of months.

NOVEMBER 15, 2019

https://www.reuters.com/

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.